# US 2023/0416942 A1 · Nanobody Compositions and Methods of Use of the Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0416942 A1
- Document ID: US20230416942A1
- Status: Published application
- Kind: A1
- Application number: 18/042,385
- Filed: 2021-08-20
- Published: 2023-12-28
- Earliest claimed: 2020-08-21
- Assignees: Yale University
- Applicants: Yale University
- Inventors: Aaron Ring; Feimei Liu
- Web page: https://patentgrep.com/patent/US20230416942A1

## CPC

- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- C40B 30/04: by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
- C07K 16/005: {constructed by phage libraries}
- C07K 16/18: against material from animals or humans
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/24: against cytokines, lymphokines or interferons
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/242: {Lymphotoxin [LT]}
- C07K 16/243: {Colony Stimulating Factors}
- C07K 16/244: {Interleukins [IL]}
- C07K 16/245: {IL-1}
- C07K 16/246: {IL-2}
- C07K 16/249: {Interferons}
- C07K 16/26: against hormones {; against hormone releasing or inhibiting factors}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2806: {against CD2}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2812: {against CD4}
- C07K 16/2815: {against CD8}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2821: {against ICAM molecules, e.g. CD50, CD54, CD102}
- C07K 16/2824: {against CD58}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/2836: {against CD106}
- C07K 16/2839: {against the integrin superfamily}
- C07K 16/2842: {against integrin beta1-subunit-containing molecules, e.g. CD29, CD49}
- C07K 16/2845: {against integrin beta2-subunit-containing molecules, e.g. CD11, CD18}
- C07K 16/2848: {against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61}
- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- C07K 16/2854: {against selectins, e.g. CD62}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/2869: {against hormone receptors (for antibodies against neuromediator receptors C07K16/286)}
- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/2881: {against CD71}
- C07K 16/2884: {against CD44}
- C07K 16/289: {against CD45}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/30: from tumour cells
- C07K 16/3007: {Carcino-embryonic Antigens}
- C07K 16/3053: {Skin, nerves, brain}
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- C07K 16/3092: {against tumour-associated mucins}
- C07K 16/36: against blood coagulation factors
- C07K 16/38: against protease inhibitors of peptide structure
- C07K 16/40: against enzymes
- C07K 16/42: against immunoglobulins
- C07K 16/4283: {against an allotypic or isotypic determinant on Ig}
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The invention provides methods for identifying nanobodies that bind with high affinity to secreted proteins or extracellular proteins, as well and compositions comprising the identified nanobodies and methods of use thereof.

## Claims

### Claim 1

An isolated antibody or antibody fragment that specifically binds to a target protein or peptide, wherein the target protein or peptide is selected from the group consisting of a secreted protein or peptide and an extracellular protein or peptide.

### Claim 2 (depends on 1)

The antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, a single chain antibody, an immunoconjugate, a glycoengineered antibody, and a bispecific antibody or other multispecific antibody.

### Claim 3 (depends on 2)

The antibody or antibody fragment of claim 2, wherein the antibody is a single chain antibody, and further wherein the single chain antibody is a nanobody.

### Claim 4 (depends on 3)

The antibody or antibody fragment of claim 3, wherein the nanobody has a predicted binding score of at least 0.5, and further wherein the predicted binding score is determined using a machine learning algorithm wherein the machine learning algorithm comprises a multi-class classifier based on a logistic regression model.

### Claim 5 (depends on 1)

The antibody or antibody fragment of claim 1, comprising an antibody or binding portion thereof that specifically binds to the secreted or extracellular protein or peptide with an affinity of at least 10−6 M.

### Claim 6 (depends on 2)

The antibody or antibody fragment of claim 2, wherein the antibody or antibody fragment comprises a therapeutic agent or a detection moiety.

### Claim 7 (depends on 2)

The antibody or antibody fragment of claim 2, wherein the antibody is selected from the group consisting of a humanized antibody, a chimeric antibody, a fully human antibody, an antibody mimetic.

### Claim 8 (depends on 3)

The antibody or antibody fragment of claim 3, wherein the secreted or extracellular protein or peptide is selected from the group consisting of a target provided in Table 2.

### Claim 9 (depends on 8)

The antibody or antibody fragment of claim 8, wherein the extracellular protein or peptide is selected from the group consisting of CCL16, CD302, CD3D, CD3E, CEACAM4, ILlORA, IL13, IL17A, IL1RN, IL21, PROCR, TIGIT, TNF, TNFRSF17, and TNFSF18.

### Claim 10 (depends on 8)

The antibody or antibody fragment of claim 8, wherein the antibody comprises at least one selected from the group consisting of: a) the heavy chain CDR1 sequence selected from the group consisting of a CDR1 of SEQ ID NO:1-SEQ ID NO:42890 comprising a sequence between the flanking sequence of SEQ ID NO:42891 and SEQ ID NO:42892; b) the heavy chain CDR2 sequence selected from the group consisting of a CDR2 of SEQ ID NO:1-SEQ ID NO:42890 comprising a sequence between the flanking sequence of SEQ ID NO:42893 and SEQ ID NO:42894; and c) the heavy chain CDR3 sequence selected from the group consisting of a CDR3 of SEQ ID NO:1-SEQ ID NO:42890 comprising a sequence between the flanking sequence of SEQ ID NO:42895 and SEQ ID NO:42896.

### Claim 11 (depends on 8)

The antibody or antibody fragment of claim 8, wherein the antibody comprises each of: a) the heavy chain CDR1 sequence selected from the group consisting of a CDR1 of SEQ ID NO:1-SEQ ID NO:42890 comprising a sequence between the flanking sequence of SEQ ID NO:42891 and SEQ ID NO:42892; b) the heavy chain CDR2 sequence selected from the group consisting of a CDR2 of SEQ ID NO:1-SEQ ID NO:42890 comprising a sequence between the flanking sequence of SEQ ID NO:42893 and SEQ ID NO:42894; and c) the heavy chain CDR3 sequence selected from the group consisting of a CDR3 of SEQ ID NO:1-SEQ ID NO:42890 comprising a sequence between the flanking sequence of SEQ ID NO:42895 and SEQ ID NO:42896, wherein each of the CDR1, CDR2 and CDR3 sequence are from the same SEQ ID NO.

### Claim 12 (depends on 8)

The antibody or antibody fragment of claim 8, wherein the antibody comprises an amino acid sequence as set forth in any one of SEQ ID NO:1-SEQ ID NO:42890.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A composition comprising an antibody or antibody fragment of any one of claims 1-12.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A nucleic acid molecule comprising a nucleotide sequence encoding an antibody or antibody fragment of any one of claims 1-12.

### Claim 15 (depends on 14)

A composition comprising a nucleic acid molecule of claim 14.

### Claim 16 (depends on 14)

An expression vector comprising the nucleic acid molecule of claim 14.

### Claim 17 (depends on 14)

A host cell comprising the nucleic acid molecule of claim 14.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising the step of administering the antibody or antibody fragment of any one of claims 1-12, the nucleic acid molecule of claim 14, or the composition of claim 13 or 15 to the subject.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of detecting a target secreted or extracellular protein or peptide in a sample, the method comprising:
a) contacting the sample with the antibody or antibody fragment of any one of claims 1-12, or the composition of claim 13, and
b) detecting binding of the antibody or antibody fragment of any one of claims 1-12, or the composition of claim 13 to the target secreted or extracellular protein or peptide.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of diagnosing a disease or disorder in a subject in need thereof, the method comprising
a. Contacting a biological sample of the subject with the antibody or antibody fragment of any one of claims 1-12, or the composition of claim 13,
b. determining the level of the target secreted or extracellular protein or peptide in the biological sample of the subject,
c. comparing the level of the target secreted or extracellular protein or peptide in the biological sample of the subject with a comparator control, and
d. diagnosing the subject with a disease or disorder associated with a differential level of the target secreted or extracellular protein or peptide when the level of the target secreted or extracellular protein or peptide in the biological sample of the subject of subject is significantly different when compared with the level of the target secreted or extracellular protein or peptide in the comparator control.

### Claim 21 (depends on 20)

The method of claim 20, comprising the further step of administering a treatment to the subject that was diagnosed as having a disease or disorder.

### Claim 22 (depends on 20)

The method of claim 20, wherein the comparator control is at least one selected from the group consisting of: a positive control, a negative control, a historical control, a historical norm, or the level of a reference molecule in the biological sample.

### Claim 23 (depends on 1)

A method of selecting an antibody or antibody fragment of claim 1, the method comprising the steps of:
a) contacting a support comprising a display library of target secreted and extracellular proteins or peptides with a phage display library of candidate antibodies or antibody fragments, such that a complex is formed between the candidate antibody and the target secreted and extracellular proteins or peptide;
b) cleaving the complex from the support using a protease;
c) isolating the nucleic acid molecule encoding the antibody or antibody fragment; and
d) sequencing the nucleic acid molecule encoding the antibody or antibody fragment.

### Claim 24 (depends on 23)

The method of claim 23, wherein the method further comprises predicting the binding score of the antibody or antibody fragment using a machine learning algorithm, wherein the machine learning algorithm comprises a multi-class classifier based on a logistic regression model.
